Vitrolife AB

GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ -- First quarter Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. Gross margin increased to 57.4% (57.1). Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. Operating cash flow amounted to SEK 69 million (198). Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85). Gothenburg, April 24, 2025 VITROLIFE AB (publ) Bronwyn Brophy O´Connor, CEO This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET. For more information, please c ontact: Helena Wennerström, acting CFO, phone: +4670 822 80 86 This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. This information was brought to you by Cision The following files are available for download: SOURCE Vitrolife AB (publ) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

GOTHENBURG, Sweden, March 5, 2025 /PRNewswire/ -- Vitrolife Group is aware that a PGT-A class action lawsuit has been filed against Vitrolife AB (publ), Vitrolife Inc and Igenomix USA, Inc in the court of the Southern District of Florida, although no formal complaint has been served yet. During the fourth quarter of 2024, similar class actions were initiated in the US against other peer companies providing PGT-A testing services. Vitrolife Group will, together with our legal counsel in the US, evaluate the class action and its potential scope and update the market in due course when further information is available. Gothenburg, 5 March 2025 VITROLIFE AB (publ) Bronwyn Brophy O'Connor, CEO Contact: Amelie Wilson, Investor Relations, [email protected] This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. This information was brought to you by Cision The following files are available for download: SOURCE Vitrolife AB (publ) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

GOTHENBURG, Sweden, Jan. 30, 2025 /PRNewswire/ -- Fourth quarter Sales of SEK 959 (904) million, an increase of 6% in local currencies and 6% in SEK. Sales per region, in local currencies was +10% in EMEA, +9% in Americas and -2% in APAC. Sales per business area, in local currencies was +12% in Consumables, +9% in Technologies and 0% in Genetics. Gross margin increased to 61.1% (56.9). Operating income before depreciation and amortisation (EBITDA) increased to SEK 337 (294) million, giving an EBITDA margin of 35.1% (32.5). Operating cash flow increased to SEK 268 million (171). Net income was SEK 139 (-4,179) million, resulting in earnings per share before dilution of SEK 1.03 (-30.86) and after dilution of SEK 1.02 (-30.86). Helena Wennerström was appointed acting CFO of Vitrolife AB (publ) effective 3 December 2024. Full year Sales of SEK 3,609 (3,512) million, an increase of 4% in local currencies and 3% in SEK. Sales per region, in local currencies was +7% in EMEA, +1% in Americas and +5% in APAC. Sales per business area, in local currencies was +10% in Consumables, +16% in Technologies and -5% in Genetics. Gross margin increased to 59.3% (56.3). Operating income before depreciation and amortisation (EBITDA) increased to SEK 1,225 (1,136) million, giving an EBITDA margin of 34.0% (32.3). Operating cash flow increased to SEK 907 million (757). Net income was SEK 514 (-3,851) million, resulting in earnings per share before dilution of SEK 3.79 (-28.44) and after dilution of SEK 3.78 (-28.44). Dividend The Board to propose to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share. Gothenburg, January 30, 2025 VITROLIFE AB (publ) Bronwyn Brophy O´Connor, CEO The information was submitted for publication, through the agency of the contact persons set out above, at 30-01-2025 08:00 CET. Contact: Helena Wennerström, acting CFO, phone: +4670 822 80 86 This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. This information was brought to you by Cision . The following files are available for download: SOURCE Vitrolife AB (publ) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED